Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

50.90USD
18 Aug 2017
Change (% chg)

$-0.02 (-0.04%)
Prev Close
$50.92
Open
$50.88
Day's High
$51.32
Day's Low
$50.42
Volume
701,043
Avg. Vol
804,970
52-wk High
$63.40
52-wk Low
$41.93

Latest Key Developments (Source: Significant Developments)

Alkermes PLC depression drug fails in two late-stage studies - Reuters
Thursday, 21 Jan 2016 07:13am EST 

Alkermes PLC:Alkermes Plc ALKS.O said its drug for major depressive disorder did not meet the main goal of improving depression symptoms in two late-stage studies - RTRS.However, a clear trend of efficacy was observed with the 2 mg dose of the drug, ALKS 5461, the company said. - RTRS.The studies were evaluated using the Montgomery–Åsberg Depression Rating Scale (MADRS), which is commonly used to measure the severity of depressive episodes in patients. - RTRS.  Full Article

Alkermes PLC announces topline results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
Thursday, 21 Jan 2016 07:00am EST 

Alkermes PLC:Announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase 3 efficacy studies to read out from the comprehensive FORWARD pivotal program for ALKS 5461.Neither of the two studies met the prespecified primary efficacy endpoint, which compared ALKS 5461 to placebo on the change from baseline on the Montgomery-Åsberg Depression Rating Scale.  Full Article

Alkermes PLC announces positive clinical trial results and streamlined registration pathway for ALKS 8700 for treatment of multiple sclerosis
Thursday, 29 Oct 2015 07:00am EDT 

Alkermes PLC:Announces positive clinical trial results and streamlined registration pathway for ALKS 8700 for treatment of multiple sclerosis.Says on track to initiate registration program for novel twice-daily oral candidate by end of 2015 and file nda in 2018.  Full Article

Alkermes PLC Says FDA Approves ARISTADA for Treatment of Schizophrenia
Monday, 5 Oct 2015 06:23pm EDT 

Alkermes Plc :FDA approves Aristada for treatment of Schizophrenia.Says Alkermes is preparing to launch ARISTADA immediately.  Full Article

BRIEF-Alkermes qtrly gaap loss per share $0.28

* Qtrly revenues increased 12% year-over-year to $218.8 million